Induction immunosuppression agents as risk factors for incident cardiovascular events and mortality after kidney transplantation.
Am J Transplant
; 19(4): 1150-1159, 2019 04.
Article
en En
| MEDLINE
| ID: mdl-30372596
Palabras clave
alemtuzumab; basiliximab/daclizumab; cardiovascular disease; clinical research/practice; coronary artery disease; graft survival; health services and outcomes research; immunosuppressant - fusion proteins and monoclonal antibodies; immunosuppression/immune modulation; kidney transplantation/nephrology
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Enfermedades Cardiovasculares
/
Trasplante de Riñón
/
Inmunosupresores
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Transplant
Asunto de la revista:
TRANSPLANTE
Año:
2019
Tipo del documento:
Article
País de afiliación:
Canadá